Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
This study is designed as a single arm Phase II clinical trial in patients with
myelofibrosis who are eligible for transplantation from a related donor or from an unrelated
donor source. Patients will be accrued into two separate strata defined by donor type. Each
of the two strata will be analyzed separately.
Patients will be followed yearly from time of enrollment into the study to assess clinical
response and overall, progression and event free survival, as well as incidence and degree
of acute and chronic GVHD. We will estimate cumulative survival and transplant related
mortality in patients enrolled in each of the two strata.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary endpoint is progression-free survival.
John Mascarenhas, MD
Icahn School of Medicine at Mount Sinai
United States: Institutional Review Board
|Roswell Park Cancer Institute||Buffalo, New York 14263|
|University of Illinois at Chicago||Chicago, Illinois 60612|
|University of Utah||Salt Lake City, Utah|
|Johns Hopkins||Baltimore, Maryland 21231|
|Weill Cornell Medical College||New York, New York 10021|
|Ohio State Univesity||Columbus, Ohio 43210|
|Icahn School of Medicine at Mount Sinai||New York, New York 10029|